Business Wire

THALES/NEURAL-LABS

13.3.2024 09:01:27 CET | Business Wire | Press release

Share
Thales Partners with Neural Labs to Support AI-Powered Smart Cities

Thales, a global leader in Software Monetization and Licensing, has expanded its partnership with Neural Labs, a company which provides video analysis for Smart Cities and AI-based Intelligent Transportation Systems (ITS), to enable secure, efficient, and practical solutions for vehicle access control and logistical planning.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240313492188/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

© Thales

Thales’s Sentinel platform provides services for software licensing, entitlement management, delivery, and protection – helping Neural Labs to quickly and efficiently automate the creation and issuance of licenses. As a result, Neural Labs was able to reduce costs and focus more on its customers, as well as the value of its software against competitors.

The relationship between Thales and Neural Labs initially started over two decades ago when Neural Labs selected Sentinel for software protection. Since then, the company has moved into a new era of digital transformation and adopted Thales Sentinel Cloud Licensing to manage its SaaS offering.

With this latest licensing iteration, Neural Labs can maximise SaaS capabilities to deploy and update licenses from any location for their entire product portfolio and growing sales teams. This partnership expansion is therefore crucial for the organisation to achieve its growth ambitions in an increasingly connected world.

Over the last three years, Neural Labs increased its revenue by nearly 25%, with Thales Sentinel playing its part by helping to reduce revenue leakage from unauthorized software use.

“We always knew that we needed to protect our software and futureproof our business. Thales has been there with us since the very beginning to help us to avoid software piracy and make the most of every market opportunity. Now, we’re working with the team even more closely to prepare our software so that 100% will be offered on the cloud. The expansion of this partnership will help us to scale with the flexible and practical solutions, and our longstanding relationship means we can move forward with full trust.” Elias Varcarcel, CEO, Neural Labs

“For over 20 years, our team has provided the technical support to help Neural Labs on its mission to make cities, towns and the road network safer, smarter and more efficient. We’re incredibly proud that Neural Lab’s confidence in our platform and services has allowed them to grow exponentially. We’re now looking ahead to the next stage – full digital transformation backed by flexible and scalable solutions.” Damien Bullot, Vice President, Software Monetization, Thales

About Neural Labs

Neural Labs has more than 20 years of experience in the development of specialized software based on reading license plates and video analytics to revolutionize various sectors such as Smart Cities, Mobility, Security, Intelligent Transport Systems (ITS), vehicle traffic management, infractions control, logistics, and vehicular access. This remarkable array of capabilities stands as a testament to Neural Labs' substantial commitment to Research and Development.

The solutions crafted by Neural Labs go above and beyond, demonstrating excellence in reading and identifying vehicle license plates (ANPR or LPR) and ISO6346 codes of transport containers (ACCR).

Neural Labs is dedicated to designing solutions that simplify the lives of its clients, transforming their environments into safer and more efficient spaces.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

* These figures exclude the ground transportation business, which is being divested

PLEASE VISIT
Thales Group
Security
@Thalesgroup

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240313492188/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release

New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release

By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release

Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye